Dihexa

Dihexa

220px
Systematic (IUPAC) name
6-{2-[2-hexanamido-3-(4-hydroxyphenyl)propanamido]-3-methylpentanamido}hexanamide
Identifiers
CAS Number	1401708-83-5
PubChem	SID: 162064814
Chemical data
Formula	C27H44N4O5
Molecular mass	504.67 g·mol−1
SMILES C(CCCCC)(=O)NC(C(=O)NC(C(=O)NCCCCCC(=O)N)C(CC)C)CC1=CC=C(C=C1)O
InChI InChI=1S/C27H44N4O5/c1-4-6-8-12-24(34)30-22(18-20-13-15-21(32)16-14-20)26(35)31-25(19(3)5-2)27(36)29-17-10-7-9-11-23(28)33/h13-16,19,22,25,32H,4-12,17-18H2,1-3H3,(H2,28,33)(H,29,36)(H,30,34)(H,31,35) Key:XEUVNVNAVKZSPT-UHFFFAOYSA-N

Dihexa (developmental code name PNB-0408), also known as N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, is an oligopeptide drug derived from angiotensin IV that binds with high affinity to hepatocyte growth factor (HGF) and potentiates its activity at its receptor, c-Met. The compound has been found to potently improve cognitive function in animal models of Alzheimer's disease-like mental impairment. In an assay of neurotrophic activity, Dihexa was found to be seven orders of magnitude more potent than brain-derived neurotrophic factor.

According to a patent, "Short duration safety studies with Dihexa have uncovered no apparent toxicity. Of particular note is a lack of neoplastic induction, since c-Met is recognized as an oncogene. This is unsurprising since oncogenesis requires multiple mutations including both oncogene induction and tumor suppressor attenuation."